Immunovaccine's financial review
Immunovaccine's Revenue (Yearly)
199K
Total Funding
8M
Last Funding Round
8M
tsx
IMV
Immunovaccine information
Immunovaccine industries
Immunovaccine's financial review
Immunovaccine's Revenue (Yearly)
199K
Total Funding
8M
Last Funding Round
8M
tsx
IMV
Technologies
Employees
Why our clients choose Apollo
“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Head of Product, Kickfurther
“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
CEO, Victorious